Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
Osteoprotegerin (OPG, Tnfrsf11b) is a secreted protein that regulates bone density. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells. Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age. OPG acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis. Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. It may also play a role in preventing arterial calcification.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
10 μg | ¥ 700 | 5日内发货 | ||
50 μg | ¥ 1,970 | 5日内发货 | ||
500 μg | ¥ 8,860 | 5日内发货 | ||
1 mg | ¥ 12,600 | 5日内发货 |
OPG Protein, Mouse, Recombinant (His) 的其他形式现货产品:
产品描述 | Osteoprotegerin (OPG, Tnfrsf11b) is a secreted protein that regulates bone density. OPG is widely expressed and constitutively released as a homodimer by mesenchymal stem cells, fibroblasts and endothelial cells. Regulation of its expression by estrogen, parathyroid hormone and cytokines is complex and changes with age. OPG acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. TRAIL decreases the release of OPG from cells that express it, while OPG inhibits TRAIL-induced apoptosis. Expression of RANK L on the cell surface, and thus its ability to stimulate osteoclastogenesis, is regulated by OPG by intracellular and extracellular mechanisms. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. It may also play a role in preventing arterial calcification. |
别名 | Opg, Ocif, Tnfrsf11b, Osteoclastogenesis inhibitory factor, Osteoprotegerin, Tumor necrosis factor receptor superfamily member 11B |
分子量 | 50-65 KDa (reducing condition) |
CAS No. | TMPJ-00253 |
Lyophilized powder: -20~-80°C for 1 year | Solution: -80°C for 6~12 month
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
OPG Protein, Mouse, Recombinant (His) TMPJ-00253 Opg Ocif Tnfrsf11b Osteoclastogenesis inhibitory factor Osteoprotegerin Tumor necrosis factor receptor superfamily member 11B Inhibitor inhibitor inhibit